This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dahia, P. L.M. Search for Related Content PubMed PubMed Citation Articles by Dahia, P. L.M.

Novel Pheochromocytoma Susceptibility Loci Identified by Integrative Genomics

Departments of ¹ Cancer Biology and ² Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School; ³ Department of Biostatistics, Harvard School of Public Health, Research Division, Joslin Diabetes Center, Boston, Massachusetts; ⁴ Interleukin Genetics, Waltham, Massachusetts; Schools of ⁵ Medicine and ⁶ Chemistry, University of São Paulo, São Paulo, São Paulo, Brazil; ⁷ Translational Research Laboratory, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain; ⁸ Broad Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; ⁹ Division of Endocrinology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts; and ¹⁰ Molecular Pathology Program, National Center for Oncological Investigation, Madrid, Spain

Requests for reprints: Patricia L.M. Dahia, Departments of Medicine and Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Room 5053-R3, MC 7880, San Antonio, TX 78229-3900. Phone: 210-567-4866; Fax: 210-567-1956; E-mail: dahia{at}uthscsa.edu.

Pheochromocytomas are catecholamine-secreting tumors that result from mutations of at least six different genes as components of distinct autosomal dominant disorders. However, there remain familial occurrences of pheochromocytoma without a known genetic defect. We describe here a familial pheochromocytoma syndrome consistent with digenic inheritance identified through a combination of global genomics strategies. Multipoint parametric linkage analysis revealed identical LOD scores of 2.97 for chromosome 2cen and 16p13 loci. A two-locus parametric linkage analysis produced maximum LOD score of 5.16 under a double recessive multiplicative model, suggesting that both loci are required to develop the disease. Allele-specific loss of heterozygosity (LOH) was detected only at the chromosome 2 locus in all tumors from this family, consistent with a tumor suppressor gene. Four additional pheochromocytomas with a similar genetic pattern were identified through transcription profiling and helped refine the chromosome 2 locus. High-density LOH mapping with single nucleotide polymorphism–based array identified a total of 18 of 62 pheochromocytomas with LOH within the chromosome 2 region, which further narrowed down the locus to <2 cM. This finding provides evidence for two novel susceptibility loci for pheochromocytoma and adds a recessive digenic trait to the increasingly broad genetic heterogeneity of these tumors. Similarly, complex traits may also be involved in other familial cancer syndromes.

This article has been cited by other articles:

				Z. Erlic, L. Rybicki, M. Peczkowska, H. Golcher, P. H. Kann, M. Brauckhoff, K. Mussig, M. Muresan, A. Schaffler, N. Reisch, et al. Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients Clin. Cancer Res., October 15, 2009; 15(20): 6378 - 6385. [Abstract] [Full Text] [PDF]

				H. P. H. Neumann and C. Eng The Approach to the Patient with Paraganglioma J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2677 - 2683. [Abstract] [Full Text] [PDF]

				F. H van Nederveen, E. Korpershoek, R. J deLeeuw, A. A Verhofstad, J. W Lenders, W. N M Dinjens, W. L Lam, and R. R de Krijger Array-comparative genomic hybridization in sporadic benign pheochromocytomas Endocr. Relat. Cancer, June 1, 2009; 16(2): 505 - 513. [Abstract] [Full Text] [PDF]

				H. J L M Timmers, A.-P. Gimenez-Roqueplo, M. Mannelli, and K. Pacak Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr. Relat. Cancer, June 1, 2009; 16(2): 391 - 400. [Abstract] [Full Text] [PDF]

				I. M. Smith, S. K. Mithani, C. Liu, S. S. Chang, S. Begum, M. Dhara, W. Westra, D. Sidranksy, and J. A. Califano Novel Integrative Methods for Gene Discovery Associated With Head and Neck Squamous Cell Carcinoma Development Arch Otolaryngol Head Neck Surg, May 1, 2009; 135(5): 487 - 495. [Abstract] [Full Text] [PDF]

				D. Taieb, F. Sebag, A. Barlier, L. Tessonnier, F. F. Palazzo, I. Morange, P. Niccoli-Sire, N. Fakhry, C. De Micco, S. Cammilleri, et al. 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? J. Nucl. Med., May 1, 2009; 50(5): 711 - 717. [Abstract] [Full Text] [PDF]

				B. Bausch, A.-C. Koschker, M. Fassnacht, J. Stoevesandt, M. M. Hoffmann, C. Eng, B. Allolio, and H. P. H. Neumann Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3478 - 3481. [Abstract] [Full Text] [PDF]